Compare PRSO & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | BNGO |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.9M |
| IPO Year | 2000 | 2018 |
| Metric | PRSO | BNGO |
|---|---|---|
| Price | $0.76 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 403.7K | 130.5K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 81.23 | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | $12,000,735.00 |
| Revenue This Year | $18.48 | $14.99 |
| Revenue Next Year | $53.57 | $34.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.99 | ★ 26.26 |
| 52 Week Low | $0.73 | $1.06 |
| 52 Week High | $2.37 | $5.50 |
| Indicator | PRSO | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 43.69 |
| Support Level | N/A | $1.08 |
| Resistance Level | $0.94 | $1.19 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 20.49 | 7.89 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.